



ASX/AIM Announcement

2 April 2026

Extension of Haleon Licensing and Supply Agreement

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that the Company, through its wholly owned subsidiary BSPS Aust Pty Ltd, has signed an extension to the existing licensing and supply agreement (the "**Agreement**") originally entered into on 16 March 2022 between the Company, Haleon UK Trading Services Ltd ("**Haleon UK**") and Olive Pharmascience Ltd. The Agreement, for the supply to Haleon UK of soft gel liquid paracetamol products, has been extended until 16 March 2027.

Eric Jiang Interim Executive Chairman said, "The Company is proud to continue its global partnership with Haleon, supporting their global brands with our innovative analgesic liquid soft gels."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)

Eric Jiang

Interim Executive Chairman

E: eric.i@wellnexlife.com.au

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson

Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)

swykeham@oranacorp.com

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker)

Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

To learn more, please visit: <https://wellnexlife.com.au/>